Pet Anthelmintic Drugs Market Analysis, Trends, and Forecast by 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Coverage: Pet Anthelmintic Drugs Market covers analysis By Target Pathogen (Ascaris Lumbricoides [Roundworm], Trichuris Trichiura [Whipworm], Enterobius Vermicularis [Pinworm], Ancylostoma Duodenale [Hookworm], Others); Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals and Clinics), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Date : Oct 2025
  • Report Code : TIPRE00013986
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Page Updated: Apr 2025

AI overview of Pet Anthelmintic Drugs Market


The Pet Anthelmintic Drugs Market is poised for significant growth, with a projected CAGR of 5.5% from 2025 to 2031. By 2024, the market size is expected to reach US$ XX million, with further expansion anticipated to reach US$ XX million by 2031. This growth is driven by increasing pet ownership and the humanization of pets, alongside a rising awareness of pet health and preventive care. Notably, trends such as the shift toward combination products and the growing adoption of oral and chewable anthelmintics are shaping the market landscape. Additionally, opportunities for partnerships with veterinary clinics and the expansion of e-commerce channels for pet medications are set to enhance the Pet Anthelmintic Drugs Market Share in the coming years.


The Pet Anthelmintic Drugs Market is expected to register a CAGR of 5.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.

The report is segmented by Target Pathogen (Ascaris Lumbricoides [Roundworm], Trichuris Trichiura [Whipworm], Enterobius Vermicularis [Pinworm], Ancylostoma Duodenale [Hookworm], Others); and Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals and Clinics). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.

Purpose of the Report

The report Pet Anthelmintic Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  • Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  • Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  • Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Pet Anthelmintic Drugs Market Segmentation

Target Pathogen

  • Ascaris Lumbricoides [Roundworm]
  • Trichuris Trichiura [Whipworm]
  • Enterobius Vermicularis [Pinworm]
  • Ancylostoma Duodenale [Hookworm]

Distribution Channel

  • Veterinary Pharmacies
  • Veterinary Hospitals and Clinics

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Pet Anthelmintic Drugs Market: Strategic Insights

pet-anthelmintic-drugs-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Pet Anthelmintic Drugs Market Growth Drivers

  • Increasing Pet Ownership and Humanization of Pets: One of the primary growth drivers in the Pet Anthelmintic Drugs market is the increasing rate of pet ownership worldwide. People treat their pet animals like family members so they take better care of their health, especially for dogs and cats. People buy more pet healthcare items for their pets including anthelmintic drugs because of this trend. People who treat their pets like family members drive up sales of anthelmintic drugs used to fight parasites. The market for pet anthelmintic drugs will expand because emerging countries will have more pet owners and these owners will need to purchase treatments to protect their animals. The market grows because pet owners understand better how deworming treatments protect their pets from parasites. As pet owners grow in number they will buy more of these products because they want to shield their pets from harm caused by worms and parasites. The pet market grows because more people own pets and spend more money on pet care products, especially in countries where people have higher incomes. Experts predict the pet anthelmintic drug market will keep expanding throughout the next few years in all regions of the world.
  • Rising Awareness of Pet Health and Preventive Care: The Pet Anthelmintic Drugs market is expanding because more people understand how to keep their pets healthy. Pet owners now understand how parasites threaten pet health so they take proactive steps to protect their animals through deworming treatments. Vets now recommend preventive treatments more often which makes pet owners buy anthelmintic drugs in large numbers. More pet owners now get their pets dewormed regularly to defend against parasites which is expanding the total market size. Pet owners now choose anthelmintic treatment types more easily because the market offers many options such as pills, chews, and topical medicines. Experts predict additional market growth for pet healthcare products so preventive care will become a main factor in market expansion. Pet owners who understand the serious health problems from untreated parasitic infections will keep getting anthelmintic treatments regularly which supports market expansion.
  • Technological Advancements in Drug Development: Modern advancements in medicine help the pet anthelmintic drugs market grow. New drug development methods help pet owners give their animals effective anthelmintic treatment through easier-to-use long-acting medicines. The market expands due to more people choosing pet deworming products because new technology helps these drugs work better. Developers now make drugs that treat various parasite types in one dose which makes these medications more attractive to customers. Due to better pet anthelmintic drugs that work well and are easy to manage, the market keeps getting bigger. The market will expand for companies when they introduce new broad-spectrum anthelmintic drugs to treat multiple parasites. The market will grow steadily because new pet medicine technology keeps improving while veterinarians and pet owners prefer modern treatments for parasites.

Pet Anthelmintic Drugs Market Future Trends

  • Shift Toward Combination Products: One of the prominent future trends in the Pet Anthelmintic Drugs market is the increasing popularity of combination products. The Pet Anthelmintic Drugs market will see more customers choose combination products in the future. Pet owners want medications that fight different types of parasites at once with easy application methods. People choose combination treatments that fight different parasites in one dose because these products save time and make medication easier to use. Market research shows combination anthelmintic drugs will take up more market space because they protect pets better against multiple parasites. Pet owners now prefer these multi-purpose treatments because they save time by treating multiple types of parasites with a single product. Market predictions show combination therapy use will keep growing because pet owners want better ways to control parasites. The market trend for combination products will grow to take more market share which will change how the industry operates. Companies will develop new all-in-one anthelmintic drugs for pets because consumers want treatments that work effectively and save them time.
  • Increased Adoption of Oral and Chewable Anthelmintics: People are moving away from traditional pet worm treatments by using oral and chewable deworming products. Pet owners prefer oral medications as topical treatments because they are now choosing chewable tablets because these products are easier to give to pets and easier for them to swallow. The pet anthelmintic segment will see more of its market growth go to chewable and oral medications because these products make life easier for both pet owners and vets. People choose these medicines because they work better and stay active for longer periods which makes them more popular. The market will see substantial changes in its distribution because consumers are seeking treatments they can use easily and that work well. Market research shows oral anthelmintic medicine will sell more because consumers want treatments that are easy to use and do their job well. The use of oral medications will drive market development especially in developed markets where pet owners invest more in their animals. Modern drug development methods now make chewables taste better and look more appealing to help pet owners choose these treatments. The pet anthelmintic market will expand further as companies gain more buyers and market share from the success of their oral and chewable products.
  • Focus on Natural and Organic Pet Medications: More pet owners now want medications derived from natural and organic ingredients to guide pet anthelmintic drug market development. People who care about their health and the environment now want to buy products that look safer and more eco-friendly. People who own pets look for natural and plant-based medicine instead of chemical drugs to treat parasites. The market for natural and plant-based anthelmintic drugs will expand because of this trend. Market data shows organic pet care products such as deworming solutions will keep increasing popularity because pet owners want wellness solutions that match their sustainability values. As pet owners worry about synthetic drug side effects they will use natural and organic anthelmintic drugs more often. The demand for natural parasite prevention products will rise as pet owners prefer these options that work effectively while giving them peace of mind. The market will keep expanding because pet owners want safer products that support the environment.

Pet Anthelmintic Drugs Market Opportunities

  • Partnerships with Veterinary Clinics and Pet Pharmacies: Strategic partnerships between pharmaceutical companies and veterinary clinics or pet pharmacies present a valuable growth opportunity in the Pet Anthelmintic Drugs market. Companies that partner with veterinary clinics and pet pharmacies gain access to pet owners who depend on their doctors for healthcare recommendations about parasites. Companies strengthen their product exposure when they team up with veterinary clinics and pharmacies which connects them with more pet owners. Veterinary clinics and pet pharmacies will use anthelmintic drugs more often which will boost market share. Through veterinary partnerships pharmaceutical companies can teach pet owners about continuous parasite control and deworming leading to more regular product purchases. Research shows that when veterinary care develops worldwide these collaborations boost market growth by bringing products to more customers and making them trust professional advice.
  • Focus on Long-Term Preventive Care Plans: The Pet Anthelmintic Drugs market can grow by introducing preventive care plans that deliver treatment results over extended periods. Pet owners prioritize their pet's health through routine check-ups and preventive care which includes deworming procedures. Pharmaceutical companies can grow their business by creating subscription or long-term treatment plans for anthelmintic drugs that help customers stay regular users and loyal clients. Pet owners who want automatic medicine refills and scheduled medication access can benefit from these plans. Market analysts predict pet anthelmintic sales growth because pet owners will use these drugs more often now that they can access long-term prevention plans. Market studies show businesses will keep using this method because pet owners want streamlined treatments for their pets. By offering subscription services pharmaceutical companies can dominate the market while building dedicated customer relationships which will fuel industry growth.
  • Growth in the E-commerce Channel for Pet Medications: Online shopping for pet medications creates a major growth path in the Pet Anthelmintic Drugs market. Internet shopping platforms now serve as primary distribution channels for pet medications including deworming products because many pet owners prefer this method of purchasing. People are moving towards digital platforms to buy pet medications because they offer better prices and easier access plus more convenient shopping. The online retail market will keep expanding because platforms let customers buy everything they need with easy subscription services. The pet healthcare market including anthelmintic drugs will grow mainly through e-commerce outlets according to market size projections. Companies that improve their digital platforms and e-commerce operations will reach more pet owners and expand their customer base. The rise of digital shopping worldwide will push pet anthelmintic products to higher market share and more growth through e-commerce channels.

Pet Anthelmintic Drugs Market Regional Insights

The regional trends and factors influencing the Pet Anthelmintic Drugs Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Pet Anthelmintic Drugs Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Pet Anthelmintic Drugs Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) 5.5%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Target Pathogen
  • Ascaris Lumbricoides [Roundworm]
  • Trichuris Trichiura [Whipworm]
  • Enterobius Vermicularis [Pinworm]
  • Ancylostoma Duodenale [Hookworm]
By Distribution Channel
  • Veterinary Pharmacies
  • Veterinary Hospitals and Clinics
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Novartis AG, 
  • Cipla Inc., 
  • Sun Pharmaceutical Industries Ltd, 
  • Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.), 
  • Zoetis, Inc., 
  • GlaxoSmithKline plc,  
  • Bayer AG, 
  • Merck & Co., Inc. (Intervet Inc.),  
  • Boehringer Ingelheim International GmbH, 
  • Virbac

  • Pet Anthelmintic Drugs Market Players Density: Understanding Its Impact on Business Dynamics

    The Pet Anthelmintic Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.


    pet-anthelmintic-drugs-market-cagr

    • Get the Pet Anthelmintic Drugs Market top key players overview

    Key Selling Points

    • Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Pet Anthelmintic Drugs Market, providing a holistic landscape.
    • Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
    • Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
    • Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

    The research report on the Pet Anthelmintic Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


    Frequently Asked Questions

    1
    What is the expected CAGR of the Pet Anthelmintic Drugs Market?
    The Pet Anthelmintic Drugs Market is estimated to witness a CAGR of 5.5% from 2025 to 2031.
    2
    What are the driving factors impacting the Pet Anthelmintic Drugs Market?
    The major factors driving the Pet Anthelmintic Drugs Market are Increasing Pet Ownership and Humanization of Pets, Rising Awareness of Pet Health and Preventive Care, and Technological Advancements in Drug Development
    3
    What are the future trends of the Pet Anthelmintic Drugs Market?
    Future trends in the Pet Anthelmintic Drugs Market are Shift Toward Combination Products, Increased Adoption of Oral and Chewable Anthelmintics, and Focus on Natural and Organic Pet Medications.
    4
    Which are the leading players in the Pet Anthelmintic Drugs Market?
    Some of the players operating in the market are  Novartis AG, Cipla Inc., Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.), Zoetis, Inc., GlaxoSmithKline plc,  Bayer AG, Merck & Co., Inc. (Intervet Inc.),  Boehringer Ingelheim International GmbH, Virbac.
    5
    What are the deliverable formats of the Pet Anthelmintic Drugs Market report?
    The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.
    6
    What are the options available for the customization of this report?
    Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Identifying Emerging Markets
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Boosting Operational Efficiency
    • Strategic Planning
    • Investment Justification
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients
    The List of Companies

    1. Novartis AG
    2. Cipla Inc.
    3. Sun Pharmaceutical Industries Ltd
    4. Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.)
    5. Zoetis, Inc.
    6. GlaxoSmithKline plc
    7. Bayer AG
    8. Merck & Co., Inc. (Intervet Inc.)
    9. Boehringer Ingelheim International GmbH
    10. Virbac

    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo